Interestingly, clinical data indicated that the TGFβ1 mRNA level in bone marrow of newly diagnosed AML was higher than in IDA patients, but TGFβR2 showed the opposite trend. This evidence concerns the gene TGFBR2 and acute myeloid leukemia.